Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC1486
Trial ID NCT02186860
Disease Acute Lymphoblastic Leukemia
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19 CAR-T cells
Generation3rd
PhasePhase1
Recruitment statusUnknown
TitleChimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Year2016
CountryChina
Company sponsorAffiliated Hospital to Academy of Military Medical Sciences
Other ID(s)307-CTC-CAR T
Vector information
Vectorlentivirus
ConstructscFv-CD28-4-1BB-CD3ζ
Transgene/Inserted geneFMC63 scFv; CD8α hinge and transmembrane; CD28 and 4-1BB signalling domains; CD3ζ.e
Vector production methodT cells from the leukapheresis product will be isolated and activated using Dynabeads Human T-Activator CD3/CD28 magnetic beads (Invitrogen Life Technologies). After 2-3 days of activation, the activated T cells will be transduced with lentivirus-expressing anti-CD19 3rd-G CAR in 24-well plates pretreated with RetroNectin (Takara) and then further expanded with X-VIVO 15 media (Lonza) containing IL-7 and IL-15 (5 ng/mL) to achieve the desired anti-CD19 3rd-G CAR-T cell dose.

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 1E6 cells/kg
Pts 5
Age Adult, Older_Adult
Lymph depletion Yes
References PMID: 28039295

Relationship Graph

Overview of Knowledge Graph